SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,141.85 |
Enterprise Value ($M) | 1,008.53 |
Book Value ($M) | 1,152.32 |
Book Value / Share | 3.94 |
Price / Book | 0.99 |
NCAV ($M) | 536.21 |
NCAV / Share | 1.83 |
Price / NCAV | 2.13 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.12 |
Return on Assets (ROA) | -0.10 |
Return on Equity (ROE) | -0.12 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.32 |
Current Ratio | 7.33 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 871.99 |
Assets | 1,488.09 |
Liabilities | 335.78 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 38.02 |
Operating Income | -237.21 |
Net Income | -146.40 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -43.88 |
Cash from Investing | -221.11 |
Cash from Financing | 10.36 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Baker Bros. Advisors Lp | 7.90 | ||
13G/A | Hansen Carl L. G. | 20.60 | 2.96 | |
13G/A | Baillie Gifford & Co | 8.29 | 22.08 | |
13D/A | Thiel Peter | 4.99 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
400,773 | 1,829,913 | 21.90 | |
362,057 | 368,523 | 98.25 | |
262,335 | 425,612 | 61.64 | |
233,266 | 296,028 | 78.80 | |
(click for more detail) |
Similar Companies | |
---|---|
ABOS – Acumen Pharmaceuticals, Inc. | ABUS – Arbutus Biopharma Corporation |